Tonix Pharmaceuticals to Present Promising Fibromyalgia Data at AAPM PainConnect 2026

Chatham, N.J. – March 3, 2026 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) today announced that a poster presentation detailing positive outcomes with Tonmya™ (cyclobenzaprine HCl sublingual tablets) will be featured at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, taking place March 5–8, 2026, in Salt Lake City, Utah.

Key Presentation Details

The poster, titled “Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia,” will be presented on March 6, 2026, at 4:55 PM ET. It is designated as Poster #50 at the conference.

Errol Gould, PhD, Vice President, Medical Affairs of Tonix Pharma, will present the findings. A copy of the presentation will be made available on the Tonix Pharmaceuticals website under the Presentations tab: https://ir.tonixpharma.com/presentations.

About Tonmya™ and Fibromyalgia

Tonmya™ (cyclobenzaprine HCl sublingual tablets 2.8mg) is Tonix’s flagship medicine and represents the first new treatment option for fibromyalgia approved in over 15 years. Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.

Tonix Pharmaceuticals: A CNS and Immunology Focused Biotech

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company concentrating on central nervous system (CNS) and immunology treatments for areas with significant unmet medical needs. Beyond Tonmya™, the company markets Zembrace® SymTouch® and Tosymra® for acute migraine.

Expanding Research Pipeline

Tonix is currently conducting Phase 2 clinical trials to explore the potential of Tonmya™ in treating major depressive disorder and acute stress disorder. The company’s pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder.